Authors: Briasoulis, E Judson, I Pavlidis, N Beale, P Wanders, J Groot, Y Veerman, G Schuessler, M Niebch, G Siamopoulos, K Tzamakou, E Rammou, D Wolf, L Walker, R Hanauske, A

Citation: E. Briasoulis et al., Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group, J CL ONCOL, 18(20), 2000, pp. 3535-3544

Authors: Nagaraja, NV Pechstein, B Erb, K Klipping, C Hermann, R Niebch, G Derendorf, H

Citation: Nv. Nagaraja et al., Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women, CLIN PHARM, 68(6), 2000, pp. 617-625

Authors: Breithaupt-Grogler, K Niebch, G Schneider, E Erb, K Hermann, R Blume, HH Schug, BS Belz, GG

Citation: K. Breithaupt-grogler et al., Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data, EUR J PH SC, 8(1), 1999, pp. 57-65

Authors: Duijkers, IJM Klipping, C Willemsen, WNP Krone, D Schneider, E Niebch, G Hermann, R

Citation: Ijm. Duijkers et al., Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers, HUM REPR, 13(9), 1998, pp. 2392-2398